ConductScience.org, home

Paper37270486

Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.

Yin M and 4 others. BMC Womens Health, 2023. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma. Papers, record 37270486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37270486

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.
PubMed
Journal
BMC Womens Health
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.39
iCite
Revised in PubMed
2023-06-20
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yin MMin
2Lu CChunli
3Zhou HHuimei
4Liu QQian
5Yang JJiaxin

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
Female
Humans
Neoplasm Recurrence, Local
Carcinoma, Ovarian Epithelial
Biomarkers
Phosphatidylinositol 3-Kinases

Source PubMed

Download CSV of topics

References63

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132651885Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?Clin Transl Oncol2021https://conductscience.org/library/papers/32651885PubMed
233236151miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1.Mol Med Rep2021https://conductscience.org/library/papers/33236151PubMed
335211759Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).Oncol Rep2022https://conductscience.org/library/papers/35211759PubMed
427794568Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.Chemotherapy2017https://conductscience.org/library/papers/27794568PubMed
536095166The Tumor Microenvironment of Clear-Cell Ovarian Cancer.Cancer Immunol Res2022https://conductscience.org/library/papers/36095166PubMed
631319139Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.Cancer Lett2019https://conductscience.org/library/papers/31319139PubMed
726053278CDK4/6 inhibitors in breast cancer.Anticancer Drugs2015https://conductscience.org/library/papers/26053278PubMed
831652965Understanding and Targeting Apoptotic Pathways in Ovarian Cancer.Cancers (Basel)2019https://conductscience.org/library/papers/31652965PubMed
925936818Broad targeting of resistance to apoptosis in cancer.Semin Cancer Biol2015https://conductscience.org/library/papers/25936818PubMed
1034982265OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.Med Oncol2022https://conductscience.org/library/papers/34982265PubMed
1135622184Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma.Cell Biol Toxicol2023https://conductscience.org/library/papers/35622184PubMed
1233168565Treatment of epithelial ovarian cancer.BMJ2020https://conductscience.org/library/papers/33168565PubMed
1331046081ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.Ann Oncol2019https://conductscience.org/library/papers/31046081PubMed
1425341576Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.Int J Gynecol Cancer2014https://conductscience.org/library/papers/25341576PubMed
1530217369Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.Gynecol Oncol2018https://conductscience.org/library/papers/30217369PubMed
1626675567Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.Cancer Cell Int2015https://conductscience.org/library/papers/26675567PubMed
1725519148Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.Mol Cancer Res2015https://conductscience.org/library/papers/25519148PubMed
1832948640Clear cell carcinoma of the ovary: a clinical and molecular perspective.Int J Gynecol Cancer2021https://conductscience.org/library/papers/32948640PubMed
1918377417Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.Cancer Sci2008https://conductscience.org/library/papers/18377417PubMed
2031046082Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.Ann Oncol2019https://conductscience.org/library/papers/31046082PubMed

See all 63 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
37761986High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer.Int J Mol Sci2023https://conductscience.org/library/papers/37761986PubMed
37525667Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1α/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma.Cancer Manag Res2023https://conductscience.org/library/papers/37525667PubMed

Download CSV of cited by

Genes27

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACE259272PubTator's text mininghttps://conductscience.org/library/genes/59272NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ANXA4307PubTator's text mininghttps://conductscience.org/library/genes/307NCBI Gene
ARID1A8289PubTator's text mininghttps://conductscience.org/library/genes/8289NCBI Gene
CASP8841PubTator's text mininghttps://conductscience.org/library/genes/841NCBI Gene
CAV1857PubTator's text mininghttps://conductscience.org/library/genes/857NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
DIABLO56616PubTator's text mininghttps://conductscience.org/library/genes/56616NCBI Gene
GRB22885PubTator's text mininghttps://conductscience.org/library/genes/2885NCBI Gene
GSK3B2932PubTator's text mininghttps://conductscience.org/library/genes/2932NCBI Gene
HNF1B6928PubTator's text mininghttps://conductscience.org/library/genes/6928NCBI Gene
IGF1R3480PubTator's text mininghttps://conductscience.org/library/genes/3480NCBI Gene
ITGA88516PubTator's text mininghttps://conductscience.org/library/genes/8516NCBI Gene
ITGB83696PubTator's text mininghttps://conductscience.org/library/genes/3696NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
MMRN122915PubTator's text mininghttps://conductscience.org/library/genes/22915NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
MUC1694025PubTator's text mininghttps://conductscience.org/library/genes/94025NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene

See all 27 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37270486

GET https://conductscience.org/api/papers/v1/37270486/references?page=2